A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream
Status:
Completed
Trial end date:
2015-09-24
Target enrollment:
Participant gender:
Summary
This will be an open-label, non-randomized, single-center study to assess the residency of
GSK2894512 in the skin of healthy adult male volunteers with normal barrier function. The
study will have two parts, Cohort 1 (Part A) followed by Cohort 2 (Part B). The study will
assess the residence time in human skin . The primary objective is to evaluate the residency
time in skin following topical application of two formulations of GSK2894512 Cream. The total
study duration will be of 15 days including 1 to 7 days of treatment period, 8 to 14 days of
post treatment period and 1 day of follow up. The screening period will be up to 28 days
prior to Baseline (Day 1).